Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The need for new clinical trials of old cardiovascular drugs

Nature Reviews Cardiology volume 20, pages 71–72 (2023)Cite this article

Subjects

While there is understandable excitement about the development of new cardiovascular drugs, an unmet and equally important need is to perform new clinical trials of old drugs, including to determine their longer-term effects and if and when they should be discontinued after years of use. New trials of old drugs can inform clinical practice and are much needed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tricoci, P., Allen, J. M., Kramer, J. M., Califf, R. M. & Smith, S. C. Jr Scientific evidence underlying the ACC/AHA clinical practice guidelines. J. Am. Med. Assoc. 301, 831–841 (2009).

    Article  CAS  Google Scholar 

  2. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709–717 (1999).

    Article  CAS  Google Scholar 

  3. Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 383, 1838–1847 (2020).

    Article  CAS  Google Scholar 

  4. Cuffe, M. S. et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. J. Am. Med. Assoc. 287, 1541–1547 (2002).

    Article  CAS  Google Scholar 

  5. Mathew, R. et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N. Engl. J. Med. 385, 516–525 (2021).

    Article  CAS  Google Scholar 

  6. HPS2-THRIVE Collaborative Group et al. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371, 203–212 (2014).

  7. Boardman, H. M. P. et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev. 3, CD002229 (2015).

    Google Scholar 

  8. Chen, Z. M. et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1622–1632 (2005).

    Article  CAS  Google Scholar 

  9. Jong, P., Yusuf, S., Rousseau, M. F., Ahn, S. A. & Bangdiwala, S. I. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 361, 1843–1848 (2003).

    Article  CAS  Google Scholar 

  10. Jaeger, B. C. et al. Longer-term all-cause and cardiovascular mortality with intensive blood pressure control: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 7, 1138–1146 (2022).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke University School of Medicine, Durham, NC, USA

    Christopher B. Granger

  2. London School of Hygiene and Tropical Medicine, London, UK

    Stuart J. Pocock

  3. Mayo Clinic College of Medicine and Science, Rochester, MN, USA

    Bernard J. Gersh

Authors
  1. Christopher B. Granger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stuart J. Pocock
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernard J. Gersh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher B. Granger.

Ethics declarations

Competing interests

C.B.G. has received consulting fees from AbbVie, Abiomed, Alnylam Pharmaceuticals, Anthos, Bayer Corporation, Boehringer Ingelheim, Boston Scientific Corporation, Bristol Myers Squibb, Cardionomics, CeleCor Therapeutics, Janssen Pharmaceutical, Medtronic, Merck, Novo Nordisk, Novartis Pharmaceutical Company, PLX Pharma, Pfizer and Philips. C.B.G. also has salary funded by Duke University grants sponsored by Boehringer Ingelheim, the Food and Drug Administration, Novartis Pharmaceutical Company and Philips. C.B.G. has equity in Tenac.io. The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Granger, C.B., Pocock, S.J. & Gersh, B.J. The need for new clinical trials of old cardiovascular drugs. Nat Rev Cardiol 20, 71–72 (2023). https://doi.org/10.1038/s41569-022-00819-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-022-00819-1

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing